Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2023

Open Access 01-12-2023 | Breast Cancer | Review

Recent advances in targeted strategies for triple-negative breast cancer

Authors: Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei, Kongming Wu

Published in: Journal of Hematology & Oncology | Issue 1/2023

Login to get access

Abstract

Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effectiveness of chemotherapy for TNBC is still limited. The search for more effective therapies is urgent. Multiple targeted therapeutic strategies have emerged according to the specific molecules and signaling pathways expressed in TNBC. These include PI3K/AKT/mTOR inhibitors, epidermal growth factor receptor inhibitors, Notch inhibitors, poly ADP-ribose polymerase inhibitors, and antibody–drug conjugates. Moreover, immune checkpoint inhibitors, for example, pembrolizumab, atezolizumab, and durvalumab, are widely explored in the clinic. We summarize recent advances in targeted therapy and immunotherapy in TNBC, with the aim of serving as a reference for the development of individualized treatment of patients with TNBC in the future.
Literature
1.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.PubMedCrossRef
2.
Yi M, Li T, Niu M, et al. Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study. Biomark Res. 2021;9:55.PubMedPubMedCentralCrossRef
3.
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24:2206–23.PubMedPubMedCentralCrossRef
4.
Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol. 2021;72:136–45.PubMedCrossRef
5.
Poteat TC, Adams MA, Malone J, et al. Delays in breast cancer care by race and sexual orientation: results from a national survey with diverse women in the United States. Cancer. 2021;127:3514–22.PubMedCrossRef
6.
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.PubMedCrossRef
7.
Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed african-american and caucasian patients: a single-institution compilation compared with the national cancer institute’s surveillance, epidemiology, and end results database. Cancer. 2007;110:876–84.PubMedCrossRef
8.
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.PubMedCrossRef
9.
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21.PubMedCrossRef
10.
Duffy MJ, McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: Where are we? Int J Cancer. 2012;131:2471–7.PubMedCrossRef
11.
Wu Q, Qian W, Sun X, Jiang S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol. 2022;15:143.PubMedPubMedCentralCrossRef
12.
Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176–98.PubMedPubMedCentralCrossRef
13.
Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.PubMedCrossRef
14.
Kumar H, Gupta NV, Jain R, et al. A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer. J Adv Res; 2023.
15.
16.
Spínola-Lasso E, Montero JC, Jiménez-Monzón R, et al. Chemical-proteomics identify Peroxiredoxin-1 as an actionable target in triple-negative breast cancer. Int J Biol Sci. 2023;19:1731–47.PubMedPubMedCentralCrossRef
17.
18.
19.
Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(428–40): e5.
20.
21.
22.
Li J, Jiang Z. Chinese society of clinical oncology breast cancer (CSCO BC) guidelines in 2022: Stratification and classification. Cancer Biol Med. 2022;19:769–73.PubMedPubMedCentralCrossRef
23.
Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res. 2013;19:6380–8.PubMedCrossRef
24.
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.PubMedPubMedCentralCrossRef
25.
Liu YR, Jiang YZ, Xu XE, et al. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res. 2016;18:33.PubMedPubMedCentralCrossRef
26.
Zhao S, Ma D, Xiao Y, et al. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance. Oncologist. 2020;25:e1481–91.PubMedPubMedCentralCrossRef
27.
Jiang YZ, Liu Y, Xiao Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the future trial. Cell Res. 2021;31:178–86.PubMedCrossRef
28.
Li T, Wang X, Qin S, et al. Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies. Biomed Pharmacother. 2023;162:114712.PubMedCrossRef
29.
30.
Luo L, Keyomarsi K. PARP inhibitors as single agents and in combination therapy: The most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opin Investig Drugs. 2022;31:607–31.PubMedPubMedCentralCrossRef
31.
Eikesdal HP, Yndestad S, Elzawahry A, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2021;32:240–9.PubMedCrossRef
32.
Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.PubMedCrossRef
33.
Robson ME, Tung N, Conte P, et al. Olympiad final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30:558–66.PubMedPubMedCentralCrossRef
34.
35.
36.
Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant Talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol. 2020;38:388–94.PubMedCrossRef
37.
Beniey M, Hubert A, Haque T, et al. Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer. Br J Cancer. 2023;128:1964–75.PubMedPubMedCentralCrossRef
38.
Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91–113.PubMedCrossRef
39.
Gerratana L, Basile D, Buono G, et al. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev. 2018;68:102–10.PubMedCrossRef
40.
Khadela A, Chavda VP, Soni S, et al. Anti-androgenic therapies targeting the luminal androgen receptor of a typical triple-negative breast cancer. Cancers (Basel). 2022;15:233.PubMedCrossRef
41.
Shi Y, Yang F, Huang D, Guan X. Androgen blockade based clinical trials landscape in triple negative breast cancer. Biochim Biophys Acta Rev Cancer. 2018;1870:283–90.PubMedCrossRef
42.
Gucalp A, Tolaney S, Isakoff SJ, et al. Phase ii trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19:5505–12.PubMedPubMedCentralCrossRef
43.
Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36:884–90.PubMedPubMedCentralCrossRef
44.
Bonnefoi H, Grellety T, Tredan O, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12–1). Ann Oncol. 2016;27:812–8.PubMedCrossRef
45.
Min A, Jang H, Kim S, et al. Androgen receptor inhibitor enhances the antitumor effect of PARP inhibitor in breast cancer cells by modulating DNA damage response. Mol Cancer Ther. 2018;17:2507–18.PubMedCrossRef
46.
47.
Lehmann BD, Abramson VG, Sanders ME, et al. TBCRC 032 Ib/II multicenter study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR (+) metastatic triple-negative breast cancer. Clin Cancer Res. 2020;26:2111–23.PubMedCrossRef
48.
Choupani E, Madjd Z, Saraygord-Afshari N, Kiani J, Hosseini A. Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells. PLoS ONE. 2022;17:e0279522.PubMedPubMedCentralCrossRef
49.
Bury M, Le Calvé B, Ferbeyre G, Blank V, Lessard F. New insights into CDK regulators: novel opportunities for cancer therapy. Trends Cell Biol. 2021;31:331–44.PubMedCrossRef
50.
Beykou M, Arias-Garcia M, Roumeliotis TI, et al. Proteomic characterization of triple negative breast cancer cells following CDK4/6 inhibition. Sci Data. 2022;9:395.PubMedPubMedCentralCrossRef
51.
Asghar US, Barr AR, Cutts R, et al. Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clin Cancer Res. 2017;23:5561–72.PubMedPubMedCentralCrossRef
52.
Abdelmalak M, Singh R, Anwer M, et al. The renaissance of CDK inhibitors in breast cancer therapy: An update on clinical trials and therapy resistance. Cancers (Basel). 2022;14:5388.PubMedCrossRef
53.
Cretella D, Fumarola C, Bonelli M, et al. Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells. Sci Rep. 2019;9:13014.PubMedPubMedCentralCrossRef
54.
Zhu X, Chen L, Huang B, et al. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer. J Exp Clin Cancer Res. 2021;40:122.PubMedPubMedCentralCrossRef
55.
56.
Teo ZL, Versaci S, Dushyanthen S, et al. Combined CDK4/6 and PI3Kα inhibition is synergistic and immunogenic in triple-negative breast cancer. Cancer Res. 2017;77:6340–52.PubMedCrossRef
57.
Cretella D, Ravelli A, Fumarola C, et al. The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. J Exp Clin Cancer Res. 2018;37:72.PubMedPubMedCentralCrossRef
58.
Lyu L, Zhang S, Deng Y, et al. Regulatory mechanisms, functions, and clinical significance of CircRNAs in triple-negative breast cancer. J Hematol Oncol. 2021;14:41.PubMedPubMedCentralCrossRef
59.
Im SA, Mukai H, Park IH, et al. Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: Results from the phase iii, randomized paloma-2 study. J Glob Oncol. 2019;5:1–19.PubMed
60.
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–36.PubMedCrossRef
61.
Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926–36.PubMedCrossRef
62.
Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–19.PubMedCrossRef
63.
Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22:212–22.PubMedCrossRef
64.
Mayer EL, Fesl C, Hlauschek D, et al. Treatment exposure and discontinuation in the palbociclib collaborative adjuvant study of PALbociclib with adjuvant endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). J Clin Oncol. 2022;40:449–58.PubMedPubMedCentralCrossRef
65.
Gnant M, Dueck AC, Frantal S, et al. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022;40:282–93.PubMedCrossRef
66.
Loibl S, Marmé F, Martin M, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial. J Clin Oncol. 2021;39:1518–30.PubMedCrossRef
67.
Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382:514–24.PubMedCrossRef
68.
Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021;32:1571–81.PubMedCrossRef
69.
Sledge GW Jr, Toi M, Neven P, et al. Monarch 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875–84.PubMedCrossRef
70.
Dey N, De P, Leyland-Jones B. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. Pharmacol Ther. 2017;175:91–106.PubMedCrossRef
71.
Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol. 2019;30:1051–60.PubMedCrossRef
72.
Chan JJ, Tan TJY, Dent RA. Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond. Ther Adv Med Oncol. 2019;11:1758835919880429.PubMedPubMedCentralCrossRef
73.
Tewari D, Patni P, Bishayee A, Sah AN, Bishayee A. Natural products targeting the PI3K-AKT-mTOR signaling pathway in cancer: A novel therapeutic strategy. Semin Cancer Biol. 2022;80:1–17.PubMedCrossRef
74.
Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005;65:10992–1000.PubMedCrossRef
75.
Li G, Robinson GW, Lesche R, et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development. 2002;129:4159–70.PubMedCrossRef
76.
Campbell IG, Russell SE, Choong DY, et al. Mutation of the PI3KCA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678–81.PubMedCrossRef
77.
Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: Role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35:515–24.PubMedCrossRef
78.
79.
Kalimutho M, Parsons K, Mittal D, et al. Targeted therapies for triple-negative breast cancer: Combating a stubborn disease. Trends Pharmacol Sci. 2015;36:822–46.PubMedCrossRef
80.
Khan MA, Jain VK, Rizwanullah M, Ahmad J, Jain K. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discov Today. 2019;24:2181–91.PubMedCrossRef
81.
Nicholson KM, Quinn DM, Kellett GL, Warr JR. LY294002, an inhibitor of phosphatidylinositol-3-kinase, causes preferential induction of apoptosis in human multidrug resistant cells. Cancer Lett. 2003;190:31–6.PubMedCrossRef
82.
Singh AR, Joshi S, George E, Durden DL. Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma model. Cancer Cell Int. 2014;14:105.PubMedPubMedCentralCrossRef
83.
Joshi S, Singh AR, Durden DL. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. Cancer Chemother Pharmacol. 2015;75:595–608.PubMedCrossRef
84.
Mahadevan D, Chiorean EG, Harris WB, et al. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and b-cell malignancies. Eur J Cancer. 2012;48:3319–27.PubMedCrossRef
85.
Deng M, Wang J, Chen Y, Zhang L, Liu D. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT/mTOR pathway. Anticancer Drugs. 2015;26:422–7.PubMedCrossRef
86.
Singh AR, Joshi S, Burgoyne AM, et al. Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma. Mol Cancer Ther. 2016;15:2553–62.PubMedPubMedCentralCrossRef
87.
Yuan Y, Long H, Zhou Z, Fu Y, Jiang B. PI3K-AKT-targeting breast cancer treatments: Natural products and synthetic compounds. Biomolecules. 2023;13:93.PubMedPubMedCentralCrossRef
88.
Banerji U, Dean EJ, Pérez-Fidalgo JA, et al. A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clin Cancer Res. 2018;24:2050–9.PubMedCrossRef
89.
de Bono JS, De Giorgi U, Rodrigues DN, et al. Randomized phase II study evaluating AKT blockade with Ipatasertib, in combination with Abiraterone, in patients with metastatic prostate cancer with and without PTEN loss. Clin Cancer Res. 2019;25:928–36.PubMedCrossRef
90.
Kalinsky K, Hong F, McCourt CK, et al. Effect of Capivasertib in patients with an AKT1 E17k-mutated tumor: NCI-match subprotocol EAY131-Y nonrandomized trial. JAMA Oncol. 2021;7:271–8.PubMedCrossRef
91.
Schmid P, Abraham J, Chan S, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial. J Clin Oncol. 2020;38:423–33.PubMedCrossRef
92.
Kim SB, Dent R, Im SA, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (lotus): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017;18:1360–72.PubMedPubMedCentralCrossRef
93.
Oliveira M, Saura C, Nuciforo P, et al. Fairlane, a double-blind placebo-controlled randomized phase II trial of neoadjuvant Ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019;30:1289–97.PubMedCrossRef
94.
95.
Omeljaniuk WJ, Krętowski R, Ratajczak-Wrona W, Jabłońska E, Cechowska-Pasko M. Novel dual PI3K/mTOR inhibitor, Apitolisib (GDC-0980), inhibits growth and induces apoptosis in human glioblastoma cells. Int J Mol Sci. 2021;22:11511.PubMedPubMedCentralCrossRef
96.
97.
98.
Cerma K, Piacentini F, Moscetti L, et al. Targeting PI3K/AKT/mTOR pathway in breast cancer: From biology to clinical challenges. Biomedicines. 2023;11:109.PubMedPubMedCentralCrossRef
99.
Sobande F, Dušek L, Matějková A, et al. EGFR in triple negative breast carcinoma: significance of protein expression and high gene copy number. Cesk Patol. 2015;51:80–6.PubMed
100.
Talukdar S, Emdad L, Das SK, Fisher PB. EGFR: an essential receptor tyrosine kinase-regulator of cancer stem cells. Adv Cancer Res. 2020;147:161–88.PubMedCrossRef
101.
Sabbah DA, Hajjo R, Sweidan K. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem. 2020;20:815–34.PubMedCrossRef
102.
Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol. 2011;55:685–96.PubMedCrossRef
103.
Corkery B, Crown J, Clynes M, O’Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol. 2009;20:862–7.PubMedCrossRef
104.
Baselga J, Gómez P, Greil R, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2013;31:2586–92.PubMedPubMedCentralCrossRef
105.
Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30:2615–23.PubMedPubMedCentralCrossRef
106.
Liu Q, He L, Li S, et al. Homer3 facilitates growth factor-mediated β-catenin tyrosine phosphorylation and activation to promote metastasis in triple negative breast cancer. J Hematol Oncol. 2021;14:6.PubMedPubMedCentralCrossRef
107.
Tang AH, Hoefer RA, Guye ML, Bear HD. Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer. Cancer Drug Resist. 2022;5:691–702.PubMedPubMedCentralCrossRef
108.
El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. Sci Rep. 2020;10:6367.PubMedPubMedCentralCrossRef
109.
Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17:318–32.PubMedCrossRef
110.
Pérez Piñero C, Giulianelli S, Lamb CA, Lanari C. New insights in the interaction of FGF/FGFR and steroid receptor signaling in breast cancer. Endocrinology. 2022;163:bqab265.PubMedCrossRef
111.
Cheng CL, Thike AA, Tan SY, et al. Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer. Breast Cancer Res Treat. 2015;151:99–111.PubMedCrossRef
112.
Lee HJ, Seo AN, Park SY, et al. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets. Ann Surg Oncol. 2014;21:1561–8.PubMedCrossRef
113.
114.
Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010;29:2013–23.PubMedPubMedCentralCrossRef
115.
André F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013;19:3693–702.PubMedCrossRef
116.
Pearson A, Smyth E, Babina IS, et al. High-level clonal FGFR amplification and response to fgfr inhibition in a translational clinical trial. Cancer Discov. 2016;6:838–51.PubMedPubMedCentralCrossRef
117.
118.
Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52:117–24.PubMedCrossRef
119.
Shiau JP, Wu CC, Chang SJ, et al. Fak regulates VEGFR2 expression and promotes angiogenesis in triple-negative breast cancer. Biomedicines. 2021;9:1789.PubMedPubMedCentralCrossRef
120.
Shashni B, Nishikawa Y, Nagasaki Y. Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles. Biomaterials. 2021;269:120645.PubMedCrossRef
121.
Robert NJ, Diéras V, Glaspy J, et al. Ribbon-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60.PubMedCrossRef
122.
Brufsky AM, Hurvitz S, Perez E, et al. Ribbon-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29:4286–93.PubMedCrossRef
123.
von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (Geparsixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15:747–56.CrossRef
124.
Gerber B, von Minckwitz G, Eidtmann H, et al. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the Geparquinto study (GBG 44). Ann Surg Oncol. 2014;21:2517–24.PubMedCrossRef
125.
Loibl S, Weber KE, Timms KM, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from Geparsixto. Ann Oncol. 2018;29:2341–7.PubMedCrossRef
126.
Bell R, Brown J, Parmar M, et al. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol. 2017;28:754–60.PubMedCrossRef
127.
Gao Z, Shi M, Wang Y, Chen J, Ou Y. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2. Pathol Res Pract. 2019;215:152422.PubMedCrossRef
128.
Yang C, Zhang J, Zhang Y, et al. Low-dose Apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (lancet): a single-center, single-arm, phase trial. Ther Adv Med Oncol. 2022;14:17588359221118052.PubMedPubMedCentralCrossRef
129.
Li DD, Tao ZH, Wang BY, et al. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the nan trial. NPJ Breast Cancer. 2022;8:110.PubMedPubMedCentralCrossRef
130.
Liu J, Liu Q, Li Y, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J Immunother Cancer. 2020;8:e000696.PubMedPubMedCentralCrossRef
131.
132.
Yuan X, Wu H, Xu H, et al. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015;369:20–7.PubMedCrossRef
133.
Weijzen S, Rizzo P, Braid M, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 2002;8:979–86.PubMedCrossRef
134.
135.
Yuan X, Wu H, Xu H, et al. Meta-analysis reveals the correlation of notch signaling with non-small cell lung cancer progression and prognosis. Sci Rep. 2015;5:10338.PubMedPubMedCentralCrossRef
136.
Zhang H, Yang Y, Li X, Yuan X, Chu Q. Targeting the notch signaling pathway and the notch ligand, dll3, in small cell lung cancer. Biomed Pharmacother. 2023;159:114248.PubMedCrossRef
137.
O’Neill CF, Urs S, Cinelli C, et al. Notch2 signaling induces apoptosis and inhibits human mda-mb-231 xenograft growth. Am J Pathol. 2007;171:1023–36.PubMedPubMedCentralCrossRef
138.
Giuli MV, Giuliani E, Screpanti I, Bellavia D, Checquolo S. Notch signaling activation as a hallmark for triple-negative breast cancer subtype. J Oncol. 2019;2019:8707053.PubMedPubMedCentralCrossRef
139.
140.
Sharma A, Paranjape AN, Rangarajan A, Dighe RR. A monoclonal antibody against human notch1 ligand-binding domain depletes subpopulation of putative breast cancer stem-like cells. Mol Cancer Ther. 2012;11:77–86.PubMedCrossRef
141.
Kume T. Ligand-dependent notch signaling in vascular formation. Adv Exp Med Biol. 2012;727:210–22.PubMedCrossRef
142.
143.
Qin JJ, Yan L, Zhang J, Zhang WD. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res. 2019;38:195.PubMedPubMedCentralCrossRef
144.
145.
146.
Wei W, Tweardy DJ, Zhang M, et al. STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. Stem Cells. 2014;32:2571–82.PubMedCrossRef
147.
Lu L, Dong J, Wang L, et al. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide. Oncogene. 2018;37:5292–304.PubMedCrossRef
148.
Zhong Y, Deng L, Shi S, et al. The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts. Acta Pharmacol Sin. 2022;43:1013–23.PubMedCrossRef
149.
Xu X, Zhang L, He X, et al. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, emt and apoptosis. Biochem Biophys Res Commun. 2018;502:160–5.PubMedCrossRef
150.
Ding MJ, Su KE, Cui GZ, et al. Association between transforming growth factor-β1 expression and the clinical features of triple negative breast cancer. Oncol Lett. 2016;11:4040–4.PubMedPubMedCentralCrossRef
151.
Pinilla K, Drewett LM, Lucey R, Abraham JE. Precision breast cancer medicine: Early stage triple negative breast cancer-a review of molecular characterisation, therapeutic targets and future trends. Front Oncol. 2022;12:866889.PubMedPubMedCentralCrossRef
152.
Bhola NE, Balko JM, Dugger TC, et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013;123:1348–58.PubMedPubMedCentralCrossRef
153.
154.
Bai X, Yi M, Jiao Y, Chu Q, Wu K. Blocking TGF-β signaling to enhance the efficacy of immune checkpoint inhibitor. Onco Targets Ther. 2019;12:9527–38.PubMedPubMedCentralCrossRef
155.
Huang X, Zhang G, Liang T. Cancer environmental immunotherapy: Starving tumor cell to death by targeting TGFβ on immune cell. J Immunother Cancer. 2021;9:e002823.PubMedPubMedCentralCrossRef
156.
Lan Y, Yeung TL, Huang H, et al. Colocalized targeting of TGF-β and pd-l1 by bintrafusp alfa elicits distinct antitumor responses. J Immunother Cancer. 2022;10:e004122.PubMedPubMedCentralCrossRef
157.
Yi M, Wu Y, Niu M, et al. Anti-TGF-β/PD-L1 bispecific antibody promotes t cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer. 2022;10:e005543.PubMedPubMedCentralCrossRef
158.
Yi M, Zhang J, Li A, et al. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1. J Hematol Oncol. 2021;14:27.PubMedPubMedCentralCrossRef
159.
Yi M, Niu M, Zhang J, et al. Combine and conquer: Manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. J Hematol Oncol. 2021;14:146.PubMedPubMedCentralCrossRef
160.
Yi M, Niu M, Wu Y, et al. Combination of oral sting agonist MSAA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. J Hematol Oncol. 2022;15:142.PubMedPubMedCentralCrossRef
161.
Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17:630–41.PubMedCrossRef
162.
Muhammad A, Forcados GE, Katsayal BS, et al. Potential epigenetic modifications implicated in triple- to quadruple-negative breast cancer transition: a review. Epigenomics. 2022;14:711–26.PubMedCrossRef
163.
Yang X, Phillips DL, Ferguson AT, et al. Synergistic activation of functional estrogen receptor (er)-alpha by DNA methyltransferase and histone deacetylase inhibition in human er-alpha-negative breast cancer cells. Cancer Res. 2001;61:7025–9.PubMed
164.
Tan B, Zhou K, Liu W, et al. RNA N(6) -methyladenosine reader YTHDC1 is essential for TGF-beta-mediated metastasis of triple negative breast cancer. Theranostics. 2022;12:5727–43.PubMedPubMedCentralCrossRef
165.
Jiang XC, Tu FH, Wei LY, et al. Discovery of a novel g-quadruplex and histone deacetylase (HDAC) dual-targeting agent for the treatment of triple-negative breast cancer. J Med Chem. 2022;65:12346–66.PubMedCrossRef
166.
Chiu HW, Yeh YL, Wang YC, et al. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model. Mol Cancer. 2016;15:46.PubMedPubMedCentralCrossRef
167.
Tan WW, Allred JB, Moreno-Aspitia A, et al. Phase I study of Panobinostat (IBH589) and letrozole in postmenopausal metastatic breast cancer patients. Clin Breast Cancer. 2016;16:82–6.PubMedCrossRef
168.
Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504.PubMedCrossRef
169.
Fedele P, Orlando L, Cinieri S. Targeting triple negative breast cancer with histone deacetylase inhibitors. Expert Opin Investig Drugs. 2017;26:1199–206.PubMedCrossRef
170.
Tucker N. Junshi biosciences announces toripalimab in combination with chemotherapy for treatment of advanced triple-negative breast cancer met primary endpoint in phase 3 clinical study. https://​bit.​ly/​3Stq86o. Accessed 22 Feb 2023.
171.
172.
Fan L, Linxiaoxi M, Wu S, et al. Future-super: A randomized, subtyping-based umbrella phase ii trial for first-line treatment of metastatic triple-negative breast cancer. Cell Res. 2023;41:3011.
173.
Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020;18:479–89.PubMedCrossRef
174.
Zhu Y, Zhu X, Tang C, Guan X, Zhang W. Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer. 2021;1876:188593.PubMedCrossRef
175.
Xu L, Zou C, Zhang S, et al. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J Hematol Oncol. 2022;15:87.PubMedPubMedCentralCrossRef
176.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.PubMedPubMedCentralCrossRef
177.
Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–18.PubMedPubMedCentralCrossRef
178.
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–29.PubMedCrossRef
179.
Girard N, Bar J, Garrido P, et al. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: Findings from the pacific-r study. J Thorac Oncol. 2023;18:181–93.PubMedCrossRef
180.
181.
Escudier B, Motzer RJ, Sharma P, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur Urol. 2017;72:368–76.PubMedCrossRef
182.
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–502.PubMedPubMedCentralCrossRef
183.
Agostinetto E, Losurdo A, Nader-Marta G, et al. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Expert Opin Investig Drugs. 2022;31:567–91.PubMedCrossRef
184.
185.
Dai M, Liu M, Yang H, Küçük C, You H. New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: Mechanisms and therapeutic opportunities. Exp Hematol Oncol. 2022;11:101.PubMedPubMedCentralCrossRef
186.
187.
Ali HR, Glont SE, Blows FM, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015;26:1488–93.PubMedCrossRef
188.
189.
Darvin P, Toor SM, Sasidharan NV, Elkord E. Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp Mol Med. 2018;50:1–11.PubMedCrossRef
190.
Tarantino P, Antonarelli G, Ascione L, Curigliano G. Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. Expert Opin Investig Drugs. 2022;31:499–513.PubMedCrossRef
191.
Wang Y, Zhang H, Liu C, et al. Immune checkpoint modulators in cancer immunotherapy: Recent advances and emerging concepts. J Hematol Oncol. 2022;15:111.PubMedPubMedCentralCrossRef
192.
Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34:2460–7.PubMedPubMedCentralCrossRef
193.
Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:397–404.PubMedCrossRef
194.
Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:405–11.PubMedCrossRef
195.
Winer EP, Lipatov O, Im SA, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (Keynote-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:499–511.PubMedCrossRef
196.
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21.PubMedCrossRef
197.
Huang M, O’Shaughnessy J, Haiderali A, et al. Q-twist analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1. Eur J Cancer. 2022;177:45–52.PubMedCrossRef
198.
Schmid P, Salgado R, Park YH, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase Ib open-label, multicohort KEYNOTE-173 study. Ann Oncol. 2020;31:569–81.PubMedCrossRef
199.
Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6:676–84.PubMedCrossRef
200.
Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556–67.PubMedCrossRef
201.
Santa-Maria CA, O’Donnell M, Nunes R, Wright JL, Stearns V. Integrating immunotherapy in early-stage triple-negative breast cancer: Practical evidence-based considerations. J Natl Compr Canc Netw. 2022;20:738–44.PubMedPubMedCentralCrossRef
202.
Fasching PA, Hein A, Kolberg HC, et al. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer—a single-arm phase II trial (Neoimmunoboost, AGO-B-041). Eur J Cancer. 2023;184:1–9.PubMedCrossRef
203.
Shah M, Osgood CL, Amatya AK, et al. FDA approval summary: Pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer. Clin Cancer Res. 2022;28:5249–53.PubMedCrossRef
204.
Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (Impassion031): A randomised, double-blind, phase 3 trial. Lancet. 2020;396:1090–100.PubMedCrossRef
205.
Narayan P, Wahby S, Gao JJ, et al. FDA approval summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1. Clin Cancer Res. 2020;26:2284–9.PubMedCrossRef
206.
Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (Impassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44–59.PubMedCrossRef
207.
Emens LA, Molinero L, Loi S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the Impassion130 study. J Natl Cancer Inst. 2021;113:1005–16.PubMedPubMedCentralCrossRef
208.
Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: impassion 130 final overall survival analysis. Ann Oncol. 2021;32:983–93.PubMedCrossRef
209.
Miles D, Gligorov J, André F, et al. Primary results from Impassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32:994–1004.PubMedCrossRef
210.
Loibl S, Untch M, Burchardi N, et al. A randomised phase ii study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019;30:1279–88.PubMedCrossRef
211.
Loibl S, Schneeweiss A, Huober J, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022;33:1149–58.PubMedCrossRef
212.
Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. “Off-the-shelf” allogeneic CAR T cells: Development and challenges. Nat Rev Drug Discov. 2020;19:185–99.PubMedCrossRef
213.
Labanieh L, Majzner RG, Klysz D, et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell. 2022;185:1745-63. e22.CrossRef
214.
215.
Xie Y, Hu Y, Zhou N, et al. CAR T-cell therapy for triple-negative breast cancer: Where we are. Cancer Lett. 2020;491:121–31.PubMedCrossRef
216.
Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor t cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139.PubMedPubMedCentralCrossRef
217.
Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12:14.PubMedPubMedCentralCrossRef
218.
Yin L, Chen GL, Xiang Z, et al. Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer. Biomed Pharmacother. 2023;162:114648.PubMedCrossRef
219.
Harrasser M, Gohil SH, Lau H, et al. Inducible localized delivery of an anti-PD-1 SCFV enhances anti-tumor activity of ror1 car-t cells in TNBC. Breast Cancer Res. 2022;24:39.PubMedPubMedCentralCrossRef
220.
221.
222.
Xia L, Zheng ZZ, Liu JY, et al. EGFR-targeted car-t cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo. Clin Transl Immunology. 2020;9:e01135.PubMedCrossRef
223.
224.
Huo W, Yang X, Wang B, et al. Biomineralized hydrogel dc vaccine for cancer immunotherapy: a boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment. Biomaterials. 2022;288:121722.PubMedCrossRef
225.
Huang L, Rong Y, Tang X, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Mol Cancer. 2022;21:45.PubMedPubMedCentralCrossRef
226.
Bai X, Zhou Y, Yokota Y, et al. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. J Exp Clin Cancer Res. 2022;41:132.PubMedPubMedCentralCrossRef
227.
Razazan A, Behravan J. Single peptides and combination modalities for triple negative breast cancer. J Cell Physiol. 2020;235:4089–108.PubMedCrossRef
228.
Overholser J, Ambegaokar KH, Eze SM, et al. Anti-tumor effects of peptide therapeutic and peptide vaccine antibody co-targeting HER-1 and HER-2 in esophageal cancer (EC) and her-1 and igf-1r in triple-negative breast cancer (TNBC). Vaccines (Basel). 2015;3:519–43.PubMedCrossRef
229.
Petrina M, Martin J, Basta S. Granulocyte macrophage colony-stimulating factor has come of age: from a vaccine adjuvant to antiviral immunotherapy. Cytokine Growth Factor Rev. 2021;59:101–10.PubMedPubMedCentralCrossRef
230.
231.
232.
Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21:141–62.PubMedCrossRef
233.
234.
Li S, Zeng H, Fan J, et al. Glutamine metabolism in breast cancer and possible therapeutic targets. Biochem Pharmacol. 2023;210:115464.PubMedCrossRef
235.
236.
237.
238.
Wu SY, Xu Y, Chen L, et al. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the future-c-plus trial. Mol Cancer. 2022;21:84.PubMedPubMedCentralCrossRef
239.
Zhu L, Liu J, Chen J, Zhou Q. The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers. J Hematol Oncol. 2021;14:206.PubMedPubMedCentralCrossRef
240.
Wang Z, Sun K, Xiao Y, et al. Niraparib activates interferon signaling and potentiates anti-pd-1 antibody efficacy in tumor models. Sci Rep. 2019;9:1853.PubMedPubMedCentralCrossRef
241.
Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132–40.PubMedPubMedCentralCrossRef
242.
Pusztai L, Yau C, Wolf DM, et al. Durvalumab with olaparib and paclitaxel for high-risk her2-negative stage ii/iii breast cancer: Results from the adaptively randomized i-spy2 trial. Cancer Cell. 2021;39:989-98. e5.CrossRef
243.
244.
Rose S. “Very compelling” results for ADC in TNBC trial. Cancer Discov. 2022;12:280–1.CrossRef
245.
Wu M, Huang W, Yang N, Liu Y. Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy. Exp Hematol Oncol. 2022;11:93.PubMedPubMedCentralCrossRef
246.
Jeon Y, Jo U, Hong J, Gong G, Lee HJ. Trophoblast cell-surface antigen 2 (Trop2) expression in triple-negative breast cancer. BMC Cancer. 2022;22:1014.PubMedPubMedCentralCrossRef
247.
Cortesi M, Zanoni M, Maltoni R, et al. Trop2 (trophoblast cell-surface antigen 2): a drug target for breast cancer. Expert Opin Ther Targets. 2022;26:593–602.PubMedCrossRef
248.
249.
Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: Final safety and efficacy results from the phase I/II immu-132-01 basket trial. Ann Oncol. 2021;32:746–56.PubMedCrossRef
250.
Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ascent study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32:1148–56.PubMedCrossRef
251.
Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–41.PubMedCrossRef
252.
Qiu S, Zhang J, Wang Z, et al. Targeting Trop-2 in cancer: Recent research progress and clinical application. Biochim Biophys Acta Rev Cancer. 2023;1878:188902.PubMedCrossRef
253.
Adams E, Wildiers H, Neven P, Punie K. Sacituzumab govitecan and trastuzumab deruxtecan: Two new antibody-drug conjugates in the breast cancer treatment landscape. ESMO Open. 2021;6:100204.PubMedPubMedCentralCrossRef
254.
Rugo HS, Bardia A, Tolaney SM, et al. Tropics-02: A phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. Future Oncol. 2020;16:705–15.PubMedCrossRef
255.
Rugo HS, Bardia A, Marmé F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2022;40:3365–76.PubMedCrossRef
256.
Furlanetto J, Marmé F, Loibl S. Sacituzumab govitecan: Past, present and future of a new antibody-drug conjugate and future horizon. Future Oncol. 2022;18:3199–215.PubMedCrossRef
257.
Demeule M, Charfi C, Currie JC, et al. The TH1902 docetaxel peptide-drug conjugate inhibits xenografts growth of human SORT1-positive ovarian and triple-negative breast cancer stem-like cells. Pharmaceutics. 2022;14:1910.PubMedPubMedCentralCrossRef
258.
Demeule M, Charfi C, Currie JC, et al. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. Cancer Sci. 2021;112:4317–34.PubMedPubMedCentralCrossRef
259.
Charfi C, Demeule M, Currie JC, et al. New peptide-drug conjugates for precise targeting of sort1-mediated vasculogenic mimicry in the tumor microenvironment of TNBC-derived mda-mb-231 breast and ovarian es-2 clear cell carcinoma cells. Front Oncol. 2021;11:760787.PubMedPubMedCentralCrossRef
260.
Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel Trop2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329–40.PubMedPubMedCentralCrossRef
261.
Shastry M, Jacob S, Rugo HS, Hamilton E. Antibody-drug conjugates targeting Trop-2: clinical development in metastatic breast cancer. Breast. 2022;66:169–77.PubMedPubMedCentralCrossRef
262.
Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097–108.PubMedCrossRef
263.
Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143–54.PubMedCrossRef
264.
Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401:105–17.PubMedCrossRef
265.
Poh A. T-dxd: New standard for HER2-low breast cancer. Cancer Discov. 2022;12:1828.CrossRef
266.
267.
Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study. J Clin Oncol. 2020;38:1887–96.PubMedPubMedCentralCrossRef
268.
269.
M-Rabet M, Cabaud O, Josselin E, et al. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann Oncol. 2017;28:769–76.PubMedCrossRef
270.
Guo P, Huang J, Zhu B, et al. A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo. Sci Adv. 2023;9:eabq7866.PubMedPubMedCentralCrossRef
271.
Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18:280–96.PubMedCrossRef
272.
Liao M, Qin R, Huang W, et al. Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies. J Hematol Oncol. 2022;15:44.PubMedPubMedCentralCrossRef
273.
Qin R, You FM, Zhao Q, et al. Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets. J Hematol Oncol. 2022;15:133.PubMedPubMedCentralCrossRef
274.
Jiang L, Gao XM, Cao J. The achilles heel of TNBCs: ferroptosis heterogeneity. Cell Metab. 2023;35:1–2.PubMedCrossRef
275.
Gan H., Huang X., Luo X., et al. A mitochondria-targeted ferroptosis inducer activated by glutathione-responsive imaging and depletion for triple negative breast cancer theranostics. Adv Healthc Mater. 2023: e2300220.
276.
Song X, Wang X, Liu Z, Yu Z. Role of GPX4-mediated ferroptosis in the sensitivity of triple negative breast cancer cells to Gefitinib. Front Oncol. 2020;10:597434.PubMedPubMedCentralCrossRef
277.
278.
Yang C, Zhang J, Liao M, et al. Folate-mediated one-carbon metabolism: a targeting strategy in cancer therapy. Drug Discov Today. 2021;26:817–25.PubMedCrossRef
279.
Zhu S, Yi M, Wu Y, Dong B, Wu K. Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Exp Hematol Oncol. 2021;10:60.PubMedPubMedCentralCrossRef
280.
Chen X, Yang M, Yin J, et al. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling. Cell Commun Signal. 2022;20:92.PubMedPubMedCentralCrossRef
281.
Li H, Yang P, Wang J, et al. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk. J Hematol Oncol. 2022;15:2.PubMedPubMedCentralCrossRef
282.
Zhang Z, Lu M, Chen C, et al. Holo-lactoferrin: the link between ferroptosis and radiotherapy in triple-negative breast cancer. Theranostics. 2021;11:3167–82.PubMedPubMedCentralCrossRef
283.
Zhang H, Zhu S, Zhou H, et al. Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer. Front Oncol. 2023;13:1098357.PubMedPubMedCentralCrossRef
284.
285.
Yang F, Xiao Y, Ding JH, et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 2023;35:84-100.e8.PubMedCrossRef
286.
287.
288.
Xu H, Jiao Y, Qin S, et al. Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine. Exp Hematol Oncol. 2018;7:30.PubMedPubMedCentralCrossRef
289.
Guillen KP, Fujita M, Butterfield AJ, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer. 2022;3:232–50.PubMedPubMedCentralCrossRef
290.
291.
Saatci O, Kaymak A, Raza U, et al. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nat Commun. 2020;11:2416.PubMedPubMedCentralCrossRef
292.
Freitas AJA, Causin RL, Varuzza MB, et al. Liquid biopsy as a tool for the diagnosis, treatment, and monitoring of breast cancer. Int J Mol Sci. 2022;23:9952.PubMedPubMedCentralCrossRef
293.
Manoochehri M, Borhani N, Gerhäuser C, et al. DNA methylation biomarkers for noninvasive detection of triple-negative breast cancer using liquid biopsy. Int J Cancer. 2023;152:1025–35.PubMedCrossRef
294.
Salvador-Coloma C, Santaballa A, Sanmartín E, et al. Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Cancer. 2020;139:119–34.PubMedCrossRef
295.
Swaminathan H, Saravanamurali K, Yadav SA. Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment. Med Oncol. 2023;40:238.PubMedCrossRef
Metadata
Title
Recent advances in targeted strategies for triple-negative breast cancer
Authors
Shuangli Zhu
Yuze Wu
Bin Song
Ming Yi
Yuheng Yan
Qi Mei
Kongming Wu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2023
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-023-01497-3

Other articles of this Issue 1/2023

Journal of Hematology & Oncology 1/2023 Go to the issue

Review

Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies

Correspondence

CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022

Research

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Correction

Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis

Research

Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia

Correspondence

Echinomycin as a promising therapeutic agent against KSHV-related malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits